Michel Farnier

13.9k citations
196 papers · 6.3k indexed · 2 hit papers · h-index 37

Michel Farnier

190 papers receiving 6.1k citations

Hit Papers

ODYSSEY FH I and FH II: 78 week results with alirocumab t...418201520262018202250010001.5k

Peers

Michel Farnier
Comparison fields: 5 of 124
  • Surgery 4.9k
  • Endocrinology, Diabetes and Metabolism 1.7k
  • Cancer Research 1.0k
  • Economics and Econometrics 1.8k
  • Cardiology and Cardiovascular Medicine 1.1k
Replace David Kallend with:
David Kallend United States
R Češka Czechia
Alexandra Langendörfer United States
Christopher Isles United Kingdom
Leiv Ose Norway
Evan A. Stein United States
HD White
R. Scott Wright United States
T. Sourjina Australia
T.R. Pedersen Denmark
Michel Farnier relative to David Kallend United States David Kallend's profile →
Citations per field
00.5×1.6×
David Kallend · 1×
Citations per year

Countries citing papers authored by Michel Farnier

Since Specialization
Citations

This map shows the geographic impact of Michel Farnier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michel Farnier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michel Farnier more than expected).

Fields of papers citing papers by Michel Farnier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michel Farnier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michel Farnier. The network helps show where Michel Farnier may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michel Farnier, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michel Farnier Line = papers co-authored together Michel Farnier links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20241
2 20248
3 20241
4 202377
5 20231
6 202211
7 202164
8 20201
9 20192
10 20177
11 201656
12
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemiabreakdown →
2015418
13 201312
14 20123
15 20108
16 20087
17 200745
18 200690
19
Ces dernières années
20021
20 199818

About Michel Farnier

Michel Farnier is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Cancer Research, having authored 196 papers that have together received 6.3k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (161 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (59 papers), Cancer, Lipids, and Metabolism (45 papers), Pharmaceutical Economics and Policy (45 papers), Health Systems, Economic Evaluations, Quality of Life (38 papers), Antiplatelet Therapy and Cardiovascular Diseases (17 papers), Diabetes Treatment and Management (11 papers) and Lipid metabolism and disorders (8 papers). The work is most often cited by research in Surgery (4.9k citations), Endocrinology, Diabetes and Metabolism (1.7k citations) and Cancer Research (1.0k citations). Michel Farnier has collaborated with scholars based in France, United States and Italy. Frequent co-authors include John J.P. Kastelein, Michel Krempf, Gisle Langslet, Christelle Lorenzato, Jennifer G. Robinson, Maurizio Averna, Robert Pordy, Umesh Chaudhari, Frederick J. Raal and Gérald Luc. Their work appears in journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026